A tale of two systems

Ind_lsh_glb_ho_1383_hi

Knee replacements are the most common joint replacement operation in Britain, with 90,000 performed each year. A few months ago I had a total knee replacement (TKR) operation in an attempt to relieve the pain and improve mobility of the joint, which had become seriously arthritic following a hockey injury several years ago.

Posted on 20/08/2014 | 0 Comments

Lyme disease - Small bite, big threat

Env_glb_ho_1747_hi

The theme of the World Health Day in April 2014 was vector-borne diseases- ‘Small Bite: Big Threat’. For many people this conjured up thoughts of Malaria, Dengue or West Nile Virus but, few people in the UK are aware that the UK’s most common vector-borne human infection is Lyme disease.[i]

Posted on 14/08/2014 | 0 Comments

Off-label prescribing – a new mechanism for payers to drive down cost

Ind_fsi_glb_ho_160_hi

Off-label prescribing is the prescription of a drug for an indication or for an age group, dose or form of administration for which it is not approved. Recently, it has become a thorny topic for the life sciences industry, regulators and healthcare payers, with high profile cases arising in France and Italy.

Posted on 24/07/2014 | 0 Comments

UK Early Access to Medicines Scheme - a new era for patient access

Ind_lsh_glb_ho_1116_hi

In one of our previous blogs we discussed the US Food and Drug Administration’s (FDA’s) introduction of the ‘breakthrough’ designation concept as a way of improving earlier access to medicines for patients with high unmet medical need. In this blog we’re focussing on the Early Access to Medicines Scheme (EAMS), a similar scheme launched by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in April 2014.

Posted on 18/07/2014 | 0 Comments

Will wearable technology transform healthcare?

Ind_tmt_glb_ve_484_hi

Wearable technology is an industry that continues to grow and adapt to meet the ever-changing needs of our world. Many health- and fitness-related technologies have multiple applications and encourage wearers to be more engaged in their own fitness, help modify behavior by reminding wearers to exercise or take medication.

Posted on 2/07/2014 | 0 Comments

Fast-tracking drugs to market – an opportunity for all stakeholders?

Bzi_col_glb_ho_1810_hi

One of the key challenges for life science research and development (R&D) is identifying which biochemical pathways and diseases to target. Given the average cost of bringing a new drug to market is now an estimated $1.3 billion dollars as revealed in our 2013 R&D ROI report, it’s clear that R&D leaders are looking to maximise their returns. However, it is also becoming increasingly clear that only those drugs that deliver additional patient benefits will gain approval and funding.

Posted on 18/06/2014 | 0 Comments

How’s your father? Improving the detection and treatment of prostate cancer

Small_logo_whiteBG_RGB3

Across the UK, prostate cancer kills one man every hour (or 10,636 every year) and is the most common cancer in men. Indeed, 40,000 men are diagnosed with prostate cancer every year and currently there are 255,000 men living with and after the disease.[i] In the UK prostate cancer survival rates are below the European average and quality of care can depend on where you live.

Posted on 12/06/2014 | 0 Comments